Hatice Ayyıldız Sevim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hatice Ayyıldız Sevim has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Galip Can Uyar
Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey
5 shared publications - Hayriye Şahinli
Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Türkiye
5 shared publications - Selahattin Çelik
Department of Medical Oncology, Ankara Etlik City Hospital, 06010 Ankara, Türkiye
4 shared publications - Salih Karatlı
Department of Medical Oncology, Ankara Etlik City Hospital, 06010 Ankara, Türkiye
3 shared publications - Goksen Inanc Imamoglu
Ankara Etlik Şehir Hastanesi
2 shared publications - Güner Akgüner
Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Türkiye
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Galenos Yayinevi in Acta Haematologica Oncologica Turcica
Concomitant Metformin Use During Nivolumab Therapy for Advanced Non-Small Cell Lung Cancer: A Real-World Analysis of Survival Outcomes
Concomitant Metformin Use During Nivolumab Therapy for Advanced Non-Small Cell Lung Cancer: A Real-World Analysis of Survival Outcomes - Acta Haematologica Oncologica Turcica
- 20 October 2026
- Published by Galenos Yayinevi in Acta Haematologica Oncologica Turcica
Open AccessConcomitant Metformin Use During Nivolumab Therapy for Advanced Non-Small Cell Lung Cancer: A Real-World Analysis of Survival Outcomes
Concomitant Metformin Use During Nivolumab Therapy for Advanced Non-Small Cell Lung Cancer: A Real-World Analysis of Survival Outcomes - Acta Haematologica Oncologica Turcica
- Open Access
- 15 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (20) , 3458
Quality of Life and Patient-Reported Outcomes During First-Line Chemotherapy in Older Patients with De Novo Metastatic Gastrointestinal Cancers: A Prospective Longitudinal Study
Background/Objectives: This study was conducted to prospectively evaluate quality of life (QoL), patient-reported outcomes, and geriatric domains during the first 3 months of first-line systemic therapy in older patients with de novo metastatic gastrointestinal cancers. Methods: This prospective longitudinal study included 90 patients aged ≥65 years receiving first-line chemotherapy-based systemic therapy. Assessments were performed at baseline, Month 1, and Month 3 using validated QoL, sleep, anxiety, cognitive, and nutritional instruments. The primary endpoint was change in EORTC QLQ-C30 Global Health Status/QoL from baseline to Month 3. Treatment tolerability, initial radiologic response, and exploratory survival outcomes were also assessed. Results: Mean Global Health Status/QoL increased from 68.1 at baseline to 71.0 at Month 3; the model-estimated mean change was +3.0 points (95% CI, −0.3 to 6.2; p = 0.071). Fatigue and appetite loss improved significantly, and normal nutritional status increased from 31.1% to 62.2% (p < 0.001). Clinically meaningful QoL improvement and deterioration occurred in 38.9% and 18.9%, respectively. Treatment intolerance occurred in 46.7%. Disease control was associated with more favorable QoL change than progressive disease (difference, 17.8 points; 95% CI, 6.0–29.7; FDR-adjusted p = 0.008). Baseline nutritional impairment (adjusted HR, 3.58) and poor sleep quality (adjusted HR, 3.30) were associated with shorter progression-free survival. Conclusions: Mean global QoL did not change significantly during the first 3 months, while several symptom and nutritional domains improved. More favorable QoL trajectories were observed with disease control, and baseline nutritional impairment and poor sleep quality were associated with shorter progression-free survival.
- 15 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (20) , 3458
Open AccessQuality of Life and Patient-Reported Outcomes During First-Line Chemotherapy in Older Patients with De Novo Metastatic Gastrointestinal Cancers: A Prospective Longitudinal Study
Background/Objectives: This study was conducted to prospectively evaluate quality of life (QoL), patient-reported outcomes, and geriatric domains during the first 3 months of first-line systemic therapy in older patients with de novo metastatic gastrointestinal cancers. Methods: This prospective longitudinal study included 90 patients aged ≥65 years receiving first-line chemotherapy-based systemic therapy. Assessments were performed at baseline, Month 1, and Month 3 using validated QoL, sleep, anxiety, cognitive, and nutritional instruments. The primary endpoint was change in EORTC QLQ-C30 Global Health Status/QoL from baseline to Month 3. Treatment tolerability, initial radiologic response, and exploratory survival outcomes were also assessed. Results: Mean Global Health Status/QoL increased from 68.1 at baseline to 71.0 at Month 3; the model-estimated mean change was +3.0 points (95% CI, −0.3 to 6.2; p = 0.071). Fatigue and appetite loss improved significantly, and normal nutritional status increased from 31.1% to 62.2% (p < 0.001). Clinically meaningful QoL improvement and deterioration occurred in 38.9% and 18.9%, respectively. Treatment intolerance occurred in 46.7%. Disease control was associated with more favorable QoL change than progressive disease (difference, 17.8 points; 95% CI, 6.0–29.7; FDR-adjusted p = 0.008). Baseline nutritional impairment (adjusted HR, 3.58) and poor sleep quality (adjusted HR, 3.30) were associated with shorter progression-free survival. Conclusions: Mean global QoL did not change significantly during the first 3 months, while several symptom and nutritional domains improved. More favorable QoL trajectories were observed with disease control, and baseline nutritional impairment and poor sleep quality were associated with shorter progression-free survival.
- Open Access
Prognostic and Treatment-Context Associations of EASIX and IPI in Extensive-Stage Small-Cell Lung Cancer Patients Receiving First-Line Therapy
Background: The comparative prognostic value of the Endothelial Activation and Stress Index (EASIX) and the Inflammatory Prognostic Index (IPI) in extensive-stage small-cell lung cancer remains unclear. This study aimed to compare the prognostic value of EASIX and IPI and assess their contribution beyond established clinical factors. Methods: This retrospective single-center study included 129 patients with de novo extensive-stage small-cell lung cancer who initiated first-line systemic therapy between December 2022 and October 2025. Pretreatment EASIX and IPI values were analyzed as log2-transformed continuous variables in multivariable Cox models. Overall survival was the primary outcome, and first-line progression-free survival was the secondary outcome. Results: During a median follow-up of 26.91 months, 116 deaths and 123 progression-or-death events occurred. Each doubling of the EASIX value was independently associated with a higher hazard of death (adjusted hazard ratio, 1.14; 95% confidence interval, 1.01–1.28; p = 0.019), whereas IPI was not independently associated with overall survival. Neither index was independently associated with first-line progression-free survival. Adding EASIX to the clinical model improved model fit and increased the C-index from 0.619 to 0.650, whereas IPI provided no additional prognostic contribution. Conclusions: EASIX may provide prognostic information beyond established clinical factors for overall survival in extensive-stage small-cell lung cancer. These findings warrant validation in larger multicenter cohorts.
Open AccessPrognostic and Treatment-Context Associations of EASIX and IPI in Extensive-Stage Small-Cell Lung Cancer Patients Receiving First-Line Therapy
Background: The comparative prognostic value of the Endothelial Activation and Stress Index (EASIX) and the Inflammatory Prognostic Index (IPI) in extensive-stage small-cell lung cancer remains unclear. This study aimed to compare the prognostic value of EASIX and IPI and assess their contribution beyond established clinical factors. Methods: This retrospective single-center study included 129 patients with de novo extensive-stage small-cell lung cancer who initiated first-line systemic therapy between December 2022 and October 2025. Pretreatment EASIX and IPI values were analyzed as log2-transformed continuous variables in multivariable Cox models. Overall survival was the primary outcome, and first-line progression-free survival was the secondary outcome. Results: During a median follow-up of 26.91 months, 116 deaths and 123 progression-or-death events occurred. Each doubling of the EASIX value was independently associated with a higher hazard of death (adjusted hazard ratio, 1.14; 95% confidence interval, 1.01–1.28; p = 0.019), whereas IPI was not independently associated with overall survival. Neither index was independently associated with first-line progression-free survival. Adding EASIX to the clinical model improved model fit and increased the C-index from 0.619 to 0.650, whereas IPI provided no additional prognostic contribution. Conclusions: EASIX may provide prognostic information beyond established clinical factors for overall survival in extensive-stage small-cell lung cancer. These findings warrant validation in larger multicenter cohorts.
- Open Access
- 1 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 526
Emergency Surgery Independently Predicts Postoperative Recurrence in Patients with Pathologic T3N0M0 Colon Cancer: A Retrospective Single-Center Cohort Study
Background and Objectives: Pathologic stage IIA (T3N0M0) colon cancer represents a heterogeneous subgroup of stage II disease with variable recurrence risk despite similar TNM staging. Although several clinicopathological high-risk features are incorporated into current treatment guidelines, the independent prognostic significance of emergency surgery remains incompletely understood. This study aimed to identify clinicopathological predictors of postoperative recurrence, with particular emphasis on the prognostic impact of emergency surgery. Materials and Methods: This retrospective single-center cohort study included 118 patients with pathologic T3N0M0 colon adenocarcinoma who underwent curative-intent surgery. Demographic, clinicopathological, treatment, and follow-up data were analyzed. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of recurrence. Because adjuvant chemotherapy was not randomly assigned, a sensitivity analysis including adjuvant chemotherapy was conducted to address confounding by indication. Disease-free survival (DFS) was evaluated using the Kaplan–Meier method. Results: During follow-up, recurrence occurred in 15 patients (12.7%). Patients with recurrence underwent emergency surgery significantly more frequently than those without recurrence (60.0% vs. 20.4%, p = 0.003). Perineural invasion and adjuvant chemotherapy were associated with recurrence in univariable analyses. In the primary multivariable model, emergency surgery remained an independent predictor of recurrence (OR 5.508, 95% CI 1.726–17.576; p = 0.004), whereas perineural invasion showed only borderline significance. In the sensitivity analysis, emergency surgery remained independently associated with recurrence (OR 4.079, 95% CI 1.207–13.779; p = 0.024), while adjuvant chemotherapy was no longer independently associated with recurrence. Kaplan–Meier analysis demonstrated significantly shorter DFS among patients undergoing emergency surgery (log-rank p = 0.002). Conclusions: Among patients with pathologic T3N0M0 colon cancer, the need for emergency surgery was associated with a higher risk of recurrence after adjustment for other clinicopathological factors. Emergency presentation may therefore serve as an additional marker for identifying patients at increased postoperative risk. Further prospective multicenter research is needed to confirm this association and to explore its potential value when combined with molecular biomarkers for individualized postoperative management.
- 1 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 526
Open AccessEmergency Surgery Independently Predicts Postoperative Recurrence in Patients with Pathologic T3N0M0 Colon Cancer: A Retrospective Single-Center Cohort Study
Background and Objectives: Pathologic stage IIA (T3N0M0) colon cancer represents a heterogeneous subgroup of stage II disease with variable recurrence risk despite similar TNM staging. Although several clinicopathological high-risk features are incorporated into current treatment guidelines, the independent prognostic significance of emergency surgery remains incompletely understood. This study aimed to identify clinicopathological predictors of postoperative recurrence, with particular emphasis on the prognostic impact of emergency surgery. Materials and Methods: This retrospective single-center cohort study included 118 patients with pathologic T3N0M0 colon adenocarcinoma who underwent curative-intent surgery. Demographic, clinicopathological, treatment, and follow-up data were analyzed. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of recurrence. Because adjuvant chemotherapy was not randomly assigned, a sensitivity analysis including adjuvant chemotherapy was conducted to address confounding by indication. Disease-free survival (DFS) was evaluated using the Kaplan–Meier method. Results: During follow-up, recurrence occurred in 15 patients (12.7%). Patients with recurrence underwent emergency surgery significantly more frequently than those without recurrence (60.0% vs. 20.4%, p = 0.003). Perineural invasion and adjuvant chemotherapy were associated with recurrence in univariable analyses. In the primary multivariable model, emergency surgery remained an independent predictor of recurrence (OR 5.508, 95% CI 1.726–17.576; p = 0.004), whereas perineural invasion showed only borderline significance. In the sensitivity analysis, emergency surgery remained independently associated with recurrence (OR 4.079, 95% CI 1.207–13.779; p = 0.024), while adjuvant chemotherapy was no longer independently associated with recurrence. Kaplan–Meier analysis demonstrated significantly shorter DFS among patients undergoing emergency surgery (log-rank p = 0.002). Conclusions: Among patients with pathologic T3N0M0 colon cancer, the need for emergency surgery was associated with a higher risk of recurrence after adjustment for other clinicopathological factors. Emergency presentation may therefore serve as an additional marker for identifying patients at increased postoperative risk. Further prospective multicenter research is needed to confirm this association and to explore its potential value when combined with molecular biomarkers for individualized postoperative management.
- Open Access
- 5 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (8) , 467
Association of Primary Tumor Resection with Survival in De Novo Stage IV Colorectal Cancer: A Retrospective Cohort Study with Propensity Score Matching
Background: The role of primary tumor resection (PTR) in patients with de novo stage IV colorectal cancer remains controversial, particularly in the context of patient selection and tumor biology. This study aimed to evaluate the association between PTR and survival outcomes and to identify clinical, molecular, and inflammatory-nutritional prognostic factors in patients with de novo stage IV colorectal cancer. Methods: Medical records of 204 patients with de novo stage IV colorectal adenocarcinoma treated at Ankara Etlik City Hospital from December 2022 to December 2025 were reviewed retrospectively. Patients were grouped according to PTR status. Baseline clinicopathological features, molecular tumor profile, metastatic disease extent, treatment characteristics, and inflammatory-nutritional markers were recorded. Survival outcomes were assessed in terms of progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method and Cox proportional hazards regression models, as well as 1:1 propensity score matching and sensitivity analyses. Results: PTR was performed in 114 patients (55.9%), while 90 patients (44.1%) did not undergo PTR. Patients who underwent PTR were younger, had better Eastern Cooperative Oncology Group (ECOG) performance status, and more frequently had single-organ metastatic disease. In the unmatched cohort, patients who underwent PTR had longer median PFS and OS than those without PTR (15.88 vs. 11.03 months and 16.14 vs. 11.54 months, respectively; both log-rank p < 0.001). In the adjusted Cox models, PTR corresponded to lower risks of progression (hazard ratio [HR]: 0.50; 95% confidence interval [CI]: 0.34–0.74; p < 0.001) and death (HR: 0.48; 95% CI: 0.30–0.77; p = 0.002), whereas BRAF mutation showed higher risks of progression (HR: 3.00; 95% CI: 1.70–5.29; p < 0.001) and death (HR: 3.42; 95% CI: 1.83–6.38; p < 0.001). In the propensity score–matched cohort comprising 50 matched pairs, PTR remained associated with a lower risk of progression or death (HR: 0.59; 95% CI: 0.40–0.87; p = 0.007), whereas its association with OS was not statistically significant (HR: 0.69; 95% CI: 0.42–1.13; p = 0.141). Sensitivity analyses generally yielded estimates favoring PTR, although the statistical significance of the association with OS varied across analyses. Patients with higher prognostic nutritional index (PNI) values showed more favorable survival outcomes. Conclusions: In this retrospective cohort, PTR was consistently associated with longer PFS, whereas its association with OS was less robust across the adjusted analyses. Because these patients had a more favorable baseline profile, these associations should be viewed with caution and in relation to patient selection. BRAF mutation and PNI emerged as important prognostic factors, supporting a multidimensional approach to survival assessment that incorporates metastatic disease burden, tumor biology, and inflammatory-nutritional status.
- 5 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (8) , 467
Open AccessAssociation of Primary Tumor Resection with Survival in De Novo Stage IV Colorectal Cancer: A Retrospective Cohort Study with Propensity Score Matching
Background: The role of primary tumor resection (PTR) in patients with de novo stage IV colorectal cancer remains controversial, particularly in the context of patient selection and tumor biology. This study aimed to evaluate the association between PTR and survival outcomes and to identify clinical, molecular, and inflammatory-nutritional prognostic factors in patients with de novo stage IV colorectal cancer. Methods: Medical records of 204 patients with de novo stage IV colorectal adenocarcinoma treated at Ankara Etlik City Hospital from December 2022 to December 2025 were reviewed retrospectively. Patients were grouped according to PTR status. Baseline clinicopathological features, molecular tumor profile, metastatic disease extent, treatment characteristics, and inflammatory-nutritional markers were recorded. Survival outcomes were assessed in terms of progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method and Cox proportional hazards regression models, as well as 1:1 propensity score matching and sensitivity analyses. Results: PTR was performed in 114 patients (55.9%), while 90 patients (44.1%) did not undergo PTR. Patients who underwent PTR were younger, had better Eastern Cooperative Oncology Group (ECOG) performance status, and more frequently had single-organ metastatic disease. In the unmatched cohort, patients who underwent PTR had longer median PFS and OS than those without PTR (15.88 vs. 11.03 months and 16.14 vs. 11.54 months, respectively; both log-rank p < 0.001). In the adjusted Cox models, PTR corresponded to lower risks of progression (hazard ratio [HR]: 0.50; 95% confidence interval [CI]: 0.34–0.74; p < 0.001) and death (HR: 0.48; 95% CI: 0.30–0.77; p = 0.002), whereas BRAF mutation showed higher risks of progression (HR: 3.00; 95% CI: 1.70–5.29; p < 0.001) and death (HR: 3.42; 95% CI: 1.83–6.38; p < 0.001). In the propensity score–matched cohort comprising 50 matched pairs, PTR remained associated with a lower risk of progression or death (HR: 0.59; 95% CI: 0.40–0.87; p = 0.007), whereas its association with OS was not statistically significant (HR: 0.69; 95% CI: 0.42–1.13; p = 0.141). Sensitivity analyses generally yielded estimates favoring PTR, although the statistical significance of the association with OS varied across analyses. Patients with higher prognostic nutritional index (PNI) values showed more favorable survival outcomes. Conclusions: In this retrospective cohort, PTR was consistently associated with longer PFS, whereas its association with OS was less robust across the adjusted analyses. Because these patients had a more favorable baseline profile, these associations should be viewed with caution and in relation to patient selection. BRAF mutation and PNI emerged as important prognostic factors, supporting a multidimensional approach to survival assessment that incorporates metastatic disease burden, tumor biology, and inflammatory-nutritional status.
- Open Access
Association Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab
Background and Objectives: The effect of bevacizumab on the morphology of non-tumoral organs remains unclear. We evaluated computed tomography (CT)- derived treatment-emergent pancreatic volume loss and examined its association with progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer receiving bevacizumab. Materials and Methods: This single-center retrospective study included 105 patients treated at Ankara Etlik City Hospital who had evaluable paired contrast-enhanced CT scans obtained before and during therapy. Pancreatic volume was measured on CT, and percentage volume loss was calculated. Clinical, laboratory, radiological, and survival data were retrospectively reviewed. Results: Mean pancreatic volume declined from 89.9 ± 6.1 mL before treatment to 83.6 ± 5.1 mL during therapy (p < 0.001). Albumin levels and platelet counts also decreased, whereas amylase, hemoglobin, and the neutrophil-to-lymphocyte ratio remained largely unchanged. In the main multivariable models, each 1% increase in pancreatic volume loss was associated with worse bevacizumab-line PFS (HR 1.06, 95% CI 1.02–1.10; p = 0.032) and OS (HR 1.08, 95% CI 1.01–1.15; p = 0.041). Percentage change in albumin was independently associated with both endpoints. Sensitivity analyses supported a more consistent association of pancreatic volume loss with PFS than with OS. Conclusions: Pancreatic volume decreased during bevacizumab-containing therapy. Greater pancreatic volume loss was associated with shorter PFS and OS; however, the association was more consistent for PFS. Prospective studies are needed to validate these findings and determine their clinical relevance.
Open AccessAssociation Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab
Background and Objectives: The effect of bevacizumab on the morphology of non-tumoral organs remains unclear. We evaluated computed tomography (CT)- derived treatment-emergent pancreatic volume loss and examined its association with progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer receiving bevacizumab. Materials and Methods: This single-center retrospective study included 105 patients treated at Ankara Etlik City Hospital who had evaluable paired contrast-enhanced CT scans obtained before and during therapy. Pancreatic volume was measured on CT, and percentage volume loss was calculated. Clinical, laboratory, radiological, and survival data were retrospectively reviewed. Results: Mean pancreatic volume declined from 89.9 ± 6.1 mL before treatment to 83.6 ± 5.1 mL during therapy (p < 0.001). Albumin levels and platelet counts also decreased, whereas amylase, hemoglobin, and the neutrophil-to-lymphocyte ratio remained largely unchanged. In the main multivariable models, each 1% increase in pancreatic volume loss was associated with worse bevacizumab-line PFS (HR 1.06, 95% CI 1.02–1.10; p = 0.032) and OS (HR 1.08, 95% CI 1.01–1.15; p = 0.041). Percentage change in albumin was independently associated with both endpoints. Sensitivity analyses supported a more consistent association of pancreatic volume loss with PFS than with OS. Conclusions: Pancreatic volume decreased during bevacizumab-containing therapy. Greater pancreatic volume loss was associated with shorter PFS and OS; however, the association was more consistent for PFS. Prospective studies are needed to validate these findings and determine their clinical relevance.
- Open Access
Quality of Life and Psychological Factors in Patients with Metastatic Prostate Cancer Receiving Androgen Receptor–Targeted Therapies: A Prospective Cross-Sectional Real-World Study
Background and Objectives: Quality of life (QoL) has become an essential outcome in patients with metastatic prostate cancer, particularly in the era of androgen receptor (AR)-targeted therapies. Although these agents improve survival, their differential impact on QoL and the role of psychological factors remain incompletely understood. This study aimed to evaluate QoL, functional outcomes, and psychological status, and to identify factors associated with poor QoL in a real-world cohort. Materials and Methods: This prospective cross-sectional, single-center observational study included 130 patients with metastatic prostate cancer receiving AR-targeted therapies (abiraterone, enzalutamide, or apalutamide/darolutamide). QoL was assessed using the EORTC QLQ-C30 questionnaire, and psychological status was evaluated using the Hospital Anxiety and Depression Scale (HADS). Patients were stratified according to treatment groups, and comparisons were performed using appropriate statistical tests. Logistic regression analyses were conducted to determine factors independently associated with poor QoL. Results: Exploratory differences in global QoL were observed among treatment groups (p = 0.007), with lower global QoL scores in the abiraterone group and numerically higher emotional and cognitive functioning scores in the enzalutamide group. Symptom analysis demonstrated higher nausea/vomiting scores in the abiraterone group (p = 0.022), whereas other symptom domains were comparable across treatment groups. In multivariable analysis, anxiety (odds ratio [OR]: 6.62) and depression (OR: 3.40) were independently associated with poor QoL, while treatment type was not independently associated with poor QoL after multivariable adjustment. Conclusions: Although unadjusted QoL scores differed across AR-targeted therapy groups, psychological factors—particularly anxiety and depression—were significantly associated with poorer QoL in patients with metastatic prostate cancer. These findings highlight the importance of integrating routine psychosocial assessment and supportive care strategies into clinical practice to optimize patient-centered outcomes. However, given the cross-sectional and exploratory nature of the study, the findings should be interpreted cautiously.
Open AccessQuality of Life and Psychological Factors in Patients with Metastatic Prostate Cancer Receiving Androgen Receptor–Targeted Therapies: A Prospective Cross-Sectional Real-World Study
Background and Objectives: Quality of life (QoL) has become an essential outcome in patients with metastatic prostate cancer, particularly in the era of androgen receptor (AR)-targeted therapies. Although these agents improve survival, their differential impact on QoL and the role of psychological factors remain incompletely understood. This study aimed to evaluate QoL, functional outcomes, and psychological status, and to identify factors associated with poor QoL in a real-world cohort. Materials and Methods: This prospective cross-sectional, single-center observational study included 130 patients with metastatic prostate cancer receiving AR-targeted therapies (abiraterone, enzalutamide, or apalutamide/darolutamide). QoL was assessed using the EORTC QLQ-C30 questionnaire, and psychological status was evaluated using the Hospital Anxiety and Depression Scale (HADS). Patients were stratified according to treatment groups, and comparisons were performed using appropriate statistical tests. Logistic regression analyses were conducted to determine factors independently associated with poor QoL. Results: Exploratory differences in global QoL were observed among treatment groups (p = 0.007), with lower global QoL scores in the abiraterone group and numerically higher emotional and cognitive functioning scores in the enzalutamide group. Symptom analysis demonstrated higher nausea/vomiting scores in the abiraterone group (p = 0.022), whereas other symptom domains were comparable across treatment groups. In multivariable analysis, anxiety (odds ratio [OR]: 6.62) and depression (OR: 3.40) were independently associated with poor QoL, while treatment type was not independently associated with poor QoL after multivariable adjustment. Conclusions: Although unadjusted QoL scores differed across AR-targeted therapy groups, psychological factors—particularly anxiety and depression—were significantly associated with poorer QoL in patients with metastatic prostate cancer. These findings highlight the importance of integrating routine psychosocial assessment and supportive care strategies into clinical practice to optimize patient-centered outcomes. However, given the cross-sectional and exploratory nature of the study, the findings should be interpreted cautiously.
- Open Access
- 13 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4608
C-Reactive Protein–Albumin–Lymphocyte Index and the Modified Glasgow Prognostic Score as Predictors of Early Mortality After Palliative Percutaneous Transhepatic Biliary Drainage in Malignant Biliary Obstruction
Background: Biliary drainage is a key component of palliative management in patients with malignant biliary obstruction. In cases where endoscopic approaches are unsuccessful or cannot be performed, percutaneous transhepatic biliary drainage (PTBD) represents an established alternative for achieving biliary decompression. The C-reactive protein–albumin–lymphocyte (CALLY) index combines inflammatory, nutritional, and immune-related parameters into a single marker, while the modified Glasgow Prognostic Score (mGPS), based on C-reactive protein and albumin concentrations, reflects the systemic inflammatory status of the patient. This study aimed to evaluate the prognostic value of the preprocedural CALLY index and mGPS in predicting 30-day mortality among patients with advanced malignant biliary obstruction undergoing palliative PTBD. Methods: This single-center retrospective study was conducted in a total of 179 patients who underwent palliative PTBD for malignant biliary obstruction at Ankara Etlik City Hospital between December 2022 and June 2025. Results: The 30-day mortality rate was 25.1%. The cut-off value for CALLY was determined as 67 based on receiver operating characteristic (ROC) curve analysis, and mGPS was categorized as 0–1 versus 2. In univariable Cox regression analyses, pancreaticobiliary tumor type, mGPS = 2, and CALLY < 67 were associated with early mortality. In multivariable Cox analysis, CALLY ≥ 67 was independently associated with a reduced risk of 30-day mortality, whereas pancreaticobiliary tumor type was independently associated with an increased risk. In the CALLY–mGPS risk stratification, 30-day mortality rates were 8.0%, 13.5%, and 44.1% in the low-, intermediate-, and high-risk groups, respectively. Conclusions: In this retrospective cohort, preprocedural inflammation- and nutrition-based markers were found to be associated with early mortality in patients with malignant biliary obstruction undergoing PTBD. Accordingly, risk stratification using readily available parameters such as CALLY and mGPS appears feasible in the preprocedural setting. The CALLY–mGPS-based approach may provide a practical framework for clinical risk assessment; however, prospective multicenter validation, including tumor-specific subgroup analyses, is warranted.
- 13 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4608
Open AccessC-Reactive Protein–Albumin–Lymphocyte Index and the Modified Glasgow Prognostic Score as Predictors of Early Mortality After Palliative Percutaneous Transhepatic Biliary Drainage in Malignant Biliary Obstruction
Background: Biliary drainage is a key component of palliative management in patients with malignant biliary obstruction. In cases where endoscopic approaches are unsuccessful or cannot be performed, percutaneous transhepatic biliary drainage (PTBD) represents an established alternative for achieving biliary decompression. The C-reactive protein–albumin–lymphocyte (CALLY) index combines inflammatory, nutritional, and immune-related parameters into a single marker, while the modified Glasgow Prognostic Score (mGPS), based on C-reactive protein and albumin concentrations, reflects the systemic inflammatory status of the patient. This study aimed to evaluate the prognostic value of the preprocedural CALLY index and mGPS in predicting 30-day mortality among patients with advanced malignant biliary obstruction undergoing palliative PTBD. Methods: This single-center retrospective study was conducted in a total of 179 patients who underwent palliative PTBD for malignant biliary obstruction at Ankara Etlik City Hospital between December 2022 and June 2025. Results: The 30-day mortality rate was 25.1%. The cut-off value for CALLY was determined as 67 based on receiver operating characteristic (ROC) curve analysis, and mGPS was categorized as 0–1 versus 2. In univariable Cox regression analyses, pancreaticobiliary tumor type, mGPS = 2, and CALLY < 67 were associated with early mortality. In multivariable Cox analysis, CALLY ≥ 67 was independently associated with a reduced risk of 30-day mortality, whereas pancreaticobiliary tumor type was independently associated with an increased risk. In the CALLY–mGPS risk stratification, 30-day mortality rates were 8.0%, 13.5%, and 44.1% in the low-, intermediate-, and high-risk groups, respectively. Conclusions: In this retrospective cohort, preprocedural inflammation- and nutrition-based markers were found to be associated with early mortality in patients with malignant biliary obstruction undergoing PTBD. Accordingly, risk stratification using readily available parameters such as CALLY and mGPS appears feasible in the preprocedural setting. The CALLY–mGPS-based approach may provide a practical framework for clinical risk assessment; however, prospective multicenter validation, including tumor-specific subgroup analyses, is warranted.
- Open Access
- 14 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy
Objective: To evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT). Methods: In this retrospective single-center study, 139 consecutive patients with HER2-positive breast cancer who received dual anti-HER2 therapy combined with anthracycline- and taxane-based neoadjuvant chemotherapy between December 2022 and February 2025 were included. Clinicopathological variables, immuno-inflammatory parameters, and the MPV/Alb ratio were analyzed. Predictors of pCR were assessed using univariable and multivariable logistic regression. Discriminative performance and an optimal cut-off for MPV/Alb were determined by receiver operating characteristic (ROC) analysis. Results: The median age was 50 years (range, 26–79), and pCR was achieved in 54.7% of patients. On univariable analyses, estrogen receptor (ER) status, progesterone receptor (PR) status, and MPV/Alb were associated with pCR. In multivariable analysis, only MPV/Alb remained an independent predictor of pCR ( p = 0.012; odds ratio [OR], 0.388; 95% confidence interval [CI], 0.185–0.813). ROC analysis identified an optimal MPV/Alb cutoff of 2.32 (AUC 0.626; 95% CI 0.535–0.720; p = 0.048), yielding 64.5% sensitivity and 58.7% specificity. Conclusions: The MPV/Alb ratio may serve as an independent predictor of pCR in HER2-positive BC undergoing NACT. As a readily obtainable, low-cost composite derived from routine laboratory tests, MPV/Alb could aid risk stratification and treatment decision-making in clinical practice.
- 14 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessMean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy
Objective: To evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT). Methods: In this retrospective single-center study, 139 consecutive patients with HER2-positive breast cancer who received dual anti-HER2 therapy combined with anthracycline- and taxane-based neoadjuvant chemotherapy between December 2022 and February 2025 were included. Clinicopathological variables, immuno-inflammatory parameters, and the MPV/Alb ratio were analyzed. Predictors of pCR were assessed using univariable and multivariable logistic regression. Discriminative performance and an optimal cut-off for MPV/Alb were determined by receiver operating characteristic (ROC) analysis. Results: The median age was 50 years (range, 26–79), and pCR was achieved in 54.7% of patients. On univariable analyses, estrogen receptor (ER) status, progesterone receptor (PR) status, and MPV/Alb were associated with pCR. In multivariable analysis, only MPV/Alb remained an independent predictor of pCR ( p = 0.012; odds ratio [OR], 0.388; 95% confidence interval [CI], 0.185–0.813). ROC analysis identified an optimal MPV/Alb cutoff of 2.32 (AUC 0.626; 95% CI 0.535–0.720; p = 0.048), yielding 64.5% sensitivity and 58.7% specificity. Conclusions: The MPV/Alb ratio may serve as an independent predictor of pCR in HER2-positive BC undergoing NACT. As a readily obtainable, low-cost composite derived from routine laboratory tests, MPV/Alb could aid risk stratification and treatment decision-making in clinical practice.